Muhammad Wasif Saif, Namrata Sonia Chandhok
Pancreatic cancer is an aggressive and devastating cancer that continues to have high 5-year mortality rates despiteadvancements in the field. Surgery remains the only curative treatment; however, most patients present with late stagedisease deemed unresectable. By refining the resection guidelines to include a borderline resectable group, as well asadvancements in neoadjuvant chemotherapy and radiation that improve resectability, we may improve upon outcomes forpatients with more invasive disease. Here we summarize and discuss findings presented at the 2014 ASCO GastrointestinalCancers Symposium (Abstracts #283, #302, #309, #274, #275, #327) that relate neoadjuvant therapeutic strategies andborderline resectable cancers.
